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Abstract: Signaling via the Wnt-related receptor tyrosine kinase-like orphan receptor 1 (ROR1) triggers
tumorigenic features associated with cancer stem cells (CSCs) and epithelial–mesenchymal transition
(EMT), while aberrant expression of ROR1 is strongly linked to advanced disease progression
and chemoresistance. Several recent studies have shown that Wnt5a binding to ROR1 promotes
oncogenic signaling by activating multiple pathways such as RhoA/Rac1 GTPases and PI3K/AKT,
which in turn could induce transcriptional coactivator YAP/TAZ or polycomb complex protein BMI-1
signaling, respectively, to sustain stemness, metastasis and ultimately drug-resistance. These data
point towards a new feedback loop during cancer development, linking Wnt5a-ROR1 signaling
activation to YAP/TAZ or BMI-1 upregulation that could play an important role in disease progression
and treatment resistance. This review focuses on the crosstalk between Wnt5a-ROR1 and YAP/TAZ
or the BMI-1 signaling network, together with the current advancements in targeted strategies for
ROR1-positive cancers.
Keywords: Wnt signaling; ROR1; Wnt5a; Hippo-YAP/TAZ; BMI-1; drug resistance; cancer stem
cells; stemness
1. Introduction
The Wnt pathway plays essential roles in development, tissue homeostasis and disease, by
transducing signals from 19 Wnt ligands via a complex network of receptors and co-receptors [1] that
can be classified into canonical (β-catenin dependent) and non-canonical (β-catenin independent)
Wnt signaling. Although there is a considerable overlap among Wnt ligands and their specific
receptors when it comes to their involvement in canonical or non-canonical Wnt signaling, it is now
accepted that the canonical Wnt pathway primarily regulates cell proliferation and differentiation,
while non-canonical Wnt signaling regulates cell polarity, adhesion, and motility [2]. Dysregulation
of Wnt signaling has been linked to a number of diseases, most notably cancer, along with other
developmental, immunological and metabolic disorders [3].
Four Wnt binding receptors belong to the receptor tyrosine kinases as well as the pseudokinase
family and are mediators of non-canonical Wnt signaling; these are receptor tyrosine kinase-like
orphan receptor 1/2 (ROR1/ROR2), protein tyrosine kinase 7/colon carcinoma kinase 4 (PTK7/CCK4),
and tyrosine protein kinase (RYK). The tyrosine kinase domains of these receptors lack several of
the canonical amino acids or motifs that are typically required for proper catalytic activity and were
unable to bind nucleotides in vitro, and are therefore considered to be “kinase dead” [4–7]. Despite
their structural alterations and impaired catalytic activity, these Wnt receptor pseudokinases have been
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implicated in the pathology of several cancers and developmental disorders [8,9], via the modulation
of their expression and crosstalk with various intracellular signaling networks.
ROR1 and ROR2 are the two members of the ROR receptor family that are strongly expressed
during fetal and embryonic development, but to a lesser extent in tissues of healthy adults [10,11].
RORs are known to regulate several cellular processes including cell division, proliferation, migration,
and chemotaxis, via the activation of planar cell polarity (PCP) and Ca2+ pathways from non-canonical
Wnt signaling [1]. Both ROR receptors share a common molecular structure consisting of an
extracellular domain (ECD) composed of an Ig-like, cysteine rich domain (CRD) and Kringle domain; a
transmembrane domain; and an intracellular domain (ICD), consisting of a tyrosine kinase-like domain,
followed by two serine/threonine domains flanking a proline-rich domain at the end of the ICD [10].
Wnt5a from the non-canonical Wnt pathway has been shown to bind to ROR1 and ROR2 and induce
receptor heterodimerization, although more studies are needed on ROR homo- or heterodimerization
mechanisms in different cellular models [12]. Moreover, other Wnt ligands have been shown to
interact with either ROR1 or ROR2 in various cellular contexts, such as Wnt16–ROR1 interaction in
TCF3-PBX1 B-cell acute lymphoblastic leukemia [13] and Wnt9a–ROR2 interaction during skeletal
development [14].
ROR signaling has been implicated in the regulation of tissue development and homeostasis,
as well as in tumorigenesis. The enhanced expression of ROR1 is associated with malignancies
of several tissues, including hematological cancers such as chronic lymphocytic leukemia (CLL),
mantle cell lymphoma (MCL), as well as ovarian, breast, prostate, lung, melanoma and colorectal
cancers (Figure 1) [15]. The high expression of ROR1 in tumor cells is known to contribute to an
enhanced rate of cell survival, proliferation, migration and chemotaxis. The binding of Wnt5a ligand
leads to ROR1 receptor dimerization and the recruitment of various adaptor proteins that trigger the
activation of downstream Rho/Rac1 GTPases [12,13,16], PI3K/AKT [17–19] and the Hippo-YAP/TAZ
pathway [19–21], contributing to several biological processes which ultimately lead to tumor progression
and chemoresistance. At the same time, elevated ROR2 expression has also been detected in many
solid tumors including melanoma, breast, prostate, renal, colorectal, ovarian and endometrial cancers
(Figure 1) [22–24]. High ROR2 expression is usually linked to the increased migration and invasiveness
of cancer cells [22]. Additionally, ROR2 was recently found to be expressed in multiple myeloma, where
it mediates the interaction between cancer cells and the bone marrow microenvironment niche [25].
Also, multipotent mesenchymal stem cells (MSCs) express ROR2 that enhances the chondrogenic
potential of these cells, which could be useful in cartilage regeneration or production [26].
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Figure 1. Expression analysis of receptor tyrosine kinase-like orphan receptor 1 (ROR1), ROR2, BMI-
1 and YAP/TAZ genes in various human cancers. RNA-Seq expression data was obtained from The 
Cancer Genome Atlas (TCGA) Research Network data portal (https://portal.gdc.cancer.gov/). 
Fragments per kilobase million (FPKM) expression values were extracted for all target genes using 
custom Python scripts and converted to transcripts per million (TPM), and finally visualized as 
boxplots utilizing the Matplotlib [27] and Seaborn [28] plotting libraries. 
Metastasis and chemoresistance are the challenges of cancer therapy. Recently, strong evidence 
has associated ROR1 expression with cancer stem cells (CSCs), epithelial–mesenchymal transition 
(EMT) and chemoresistance, making this receptor a critical factor in tumor metastasis and recurrence 
[29,30]. Interestingly, in tumors such as breast cancer, enhanced ROR1 expression promotes 
tumorigenesis through the upregulation of YAP/TAZ transcription and/or polycomb complex 
protein BMI-1 expression. This indicates new crosstalk by which the non-canonical Wnt pathway, via 
Wnt5a-ROR1 engagement, could sustain malignant transformation [19–21,31]. This is important as 
YAP/TAZ transcription factors are both frequently altered in many types of cancers [32,33], while 
elevated BMI-1 was also reported to be important for tumorigenesis [34]. The Wnt5a-ROR1-
dependent upregulation of YAP/TAZ and BMI-1 points toward a new positive feedback loop that 
may play an important role in mediating cancer stemness, tumorigenesis and drug resistance. 
Recent clinical strategies have focused on the direct targeting of ROR1 using monoclonal 
antibodies (mAbs). Many ROR1 mAbs have been designed and demonstrate significant preclinical 
efficacy [35–37]; cirmtuzumab (UC-951) [38] is currently in phase I–II of clinical trials for CLL and 
breast cancer. Encouraging preclinical studies suggest that the concomitant suppression of ROR1 and 
other oncogenic pathways may be helpful in attaining greater clinical benefits [13,20,39,40]. This 
review focuses on the latest advances in our understanding regarding the crosstalk of Wnt5a-ROR1 
and Hippo-YAP/TAZ or BMI-1 in tumorigenesis and drug resistance and discusses novel strategies 
for the therapeutic targeting of ROR1 in cancer treatment. 
2. ROR1 Expression Is Linked to the CSC Phenotype and the Development of Chemoresistance 
The existence of the cancer stem cell (CSC) has emerged recently as increasingly relevant in 
regards to tumor development, metastasis, recurrence and drug resistance [41]. CSCs are defined as 
Figure 1. Expression analysis of receptor tyrosine kinase-li e r a rece t r 1 ( 1), 2, I-1
and YAP/TAZ genes in various h man cancers. RNA-Seq expression data was obtained from The Cancer
Genome Atlas (TCGA) Research Network data portal (https:// ortal.gdc.cancer.gov/). Fragments per
kilobase million (FPKM) expression values were extracted for all target genes using custom Python
scripts and converted to transcripts per million (TPM), and finally visualized as boxplots utilizing the
Matplotlib [27] and Seaborn [28] plotting libraries.
Metastasis and chemoresi tance are the challenges of cancer therapy. Rec ntly, strong evidence has
associated ROR1 expression with cancer stem cells (CSCs), epithelial–mesenchymal transitio (EMT)
and chemoresistanc , m king this recepto a critical factor in tumor metastasis and recurren e [29,30].
Interestingly, in tumors such as breast cancer, nhanced ROR1 expression promotes tumorigenesis
through the upregulation of YAP/TAZ transcription and/or polycomb complex protein BMI-1 expression.
This indicates new crosstalk by which the non-canonical Wnt pathway, via Wnt5a-ROR1 engagement,
could sustain malignant transformation [19–21,31]. This is important as YAP/TAZ transcription factors
are both frequently altered in many types of cancers [32,33], while elevated BMI-1 was also reported
to be important for tumorigenesis [34]. The Wnt5a-ROR1-dependent upregulation of YAP/TAZ and
BMI-1 points toward a new positive feedback loop that may play an important role in mediating cancer
stemness, tumorigenesis and drug resistance.
Recent clinical strategies have focused on the direct targeting of ROR1 using monoclonal antibodies
(mAbs). Many ROR1 mAbs have been designed and demonstrate significant preclinical efficacy [35–37];
cirmtuzumab (UC-951) [38] is currently in phase I–II of clinical trials for CLL and breast cancer.
Encouraging preclinical studies suggest that the concomitant suppression of ROR1 and other oncogenic
pathways may be helpful in attaining greater clinical benefits [13,20,39,40]. This review focuses on the
latest advances in our understanding regarding the crosstalk of Wnt5a-ROR1 and Hippo-YAP/TAZ or
BMI-1 in tumorigenesis and drug resistance and discusses novel strategies for the therapeutic targeting
of ROR1 in cancer treatment.
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2. ROR1 Expression Is Linked to the CSC Phenotype and the Development of Chemoresistance
The existence of the cancer stem cell (CSC) has emerged recently as increasingly relevant in
regards to tumor development, metastasis, recurrence and drug resistance [41]. CSCs are defined as
a subpopulation of cancer cells endowed with self-renewal and differentiation properties, through
stemness pathways, such as Wnt, TGF-β, STAT, and Hippo-YAP/TAZ, among others. Although
their origin remains elusive [42], CSCs are important contributors to intratumoral heterogeneity and
are strongly associated with disease recurrence and treatment resistance [43]. The identification of
several CSC markers has facilitated the screening and study of many cancers, including those of the
blood, breast, ovaries, brain, lung, colon and skin [44]. Currently, CD133, CD24, CD44 and aldehyde
dehydrogenase 1 (ALDH1) are widely used to identify CSCs in various tumors, while other markers
such as BMI-1 [45] and ROR1 [20,46,47] are starting to gain more attention for their involvement in
the stemness of several malignancies. ROR1 has been associated with the CSC phenotype in several
malignancies such as leukemia, ovarian and breast tumors. The majority of CLL patients express ROR1
on their neoplastic B cells that possess stemness properties such as self-renewal and differentiation [38],
while the expression of ROR1 in mouse models of CLL demonstrated the activation of signaling
networks implicated in CSC self-renewal [48]. Furthermore, high ROR1 levels in CLL patient samples
correlated with relatively short overall survival rates. Further evidence for ROR1 involvement in
CSCs has emerged from studies of ovarian and breast cancers. Ovarian cancers with high levels of
ROR1 have stem cell-like gene expression signatures, as demonstrated by high levels of ALDH1 [47]
or the cell surface expression of CD133 and CD44 [49]. Moreover, ROR1-positive ovarian CSCs have
an enhanced ability to seed metastasis, form tumor spheroids, engraft immune-deficient mice, and
migrate better, making ROR1 a prognostic marker for the shorter overall survival of ovarian cancer
patients [50]. Similarly, breast cancer cells with high ROR1 expression rates have elevated levels
of stemness signature genes (Nanog, Oct4, and Sox2) and an increased ability to migrate and form
spheroids or engraftments in immune-deficient mice, strongly indicating that ROR1 could be a marker
for CSCs in breast tumors [20]. Conclusively, these findings emphasize a key functional role for ROR1
that could contribute to the biological phenotypes associated with CSCs.
High levels of ROR1 expression in various malignancies are functionally relevant to mediate
drug resistance and are usually associated with advanced disease stages. For example, ovarian and
breast cancer tumors with high levels of ROR1 were typically poorly differentiated and associated
with an aggressive disease stage [20,51]. Recent studies have also shown that acquired resistance
to T-DM1 (trastuzumab emtansine, a newly developed antibody-drug conjugate) in HER2+ breast
cancer patients induced high ROR1 expression on neoplastic cells that exhibit stem cell signatures
(such as expression of both CD44 and ALDH1), resulting in an enhanced capacity to form spheroids
and self-renewal properties [21]. In another disease model, resistance to the MEK inhibitor trametinib
in uveal melanoma was associated with the upregulation of ROR1 and YAP/TAZ signaling, resulting
in treatment resistance in preclinical models. The inhibition of the MEK pathway led to an increase
in AKT phosphorylation, which was partially due to the Wnt5a-mediated activation of ROR1/ROR2,
while the subsequent silencing of RORs resulted in a decreased AKT phosphorylation. On the other
hand, trametinib treatment led to a strong induction of G-protein coupled receptors (GPCRs) that in
turn upregulated YAP signaling via a release of ET-3 (endotelin-3)—in this way, YAP is activated in
an autocrine fashion through EDNRB (endothelin receptor B) [19]. This is a good example of how
cancer cells could employ several “escape” routes to overcome treatment inhibition and ultimately
develop resistance.
Interestingly, a recent transcriptomic and proteomic analysis of breast cancer models showed that
the stress hormone pathway effectively induces metastasis development with a distinct phenotype [52].
High GC (glucocorticoid) levels increased tumor heterogeneity and metastasis by upregulating some
of the non-canonical Wnt pathway genes, highlighted by ROR1 expression. A transcriptome analysis
of breast cancer metastasis indicated a direct correlation between ROR1 levels and GR (glucocorticoid
receptor) signaling activation. GR activation increased metastatic breast cancer development in a
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ROR1-dependent manner, while decreasing the efficacy of paclitaxel. Cancer cells with upregulated
ROR1 could be a good opportunity for targeted therapies, where the deleterious effect of GR activation
in stress hormone-induced metastasis is prevented by ROR1 inhibition, resulting in cancer cell death.
Given the above examples, it is now more clear that ROR1 expression triggers disease progression
and drug resistance via CSC development, suggesting that ROR1 could also be used as a CSC marker,
at least for some tumors such as breast and ovarian cancers.
3. Wnt5a-ROR1 Signaling Upregulates BMI-1 to Sustain Stemness and Drug Resistance
ROR1 signaling that contributes to the maintenance, self-renewal, and drug resistance of CSCs has
been uncovered for some cancers. In breast cancer, Wnt5a binding to ROR1 increases BMI-1 levels and
this process was dependent on AKT phosphorylation [20]. The knockdown of ROR1 expression or the
blocking of ROR1 signaling with cirmtuzumab impaired Wnt5a-mediated AKT phosphorylation and
BMI-1 accumulation, clearly indicating that the intracellular signaling downstream ROR1 is involved in
BMI-1 expression modulation. Interestingly, Wnt5a-mediated BMI-1 upregulation in breast cancer cells
was observed only at the protein level and not at the mRNA level, indicating that this process is not
regulated via transcriptional activation. Previous reports have shown that phosphorylated AKT could
elevate BMI-1 levels to modulate its oncogenic function [53]. Indeed, blocking the AKT phosphorylation
downstream Wnt5a-ROR1 signaling activation resulted in a loss of BMI-1 upregulation, indicating that
the activation of AKT is the switch for BMI-1 expression modulation.
Similar findings have been described in the T-DM1-induced drug resistance of breast cancer cells,
which resulted in elevated ROR1 levels [21]. Consequently, cancer cells expressing ROR1 at higher
levels had increased BMI-1 expression and stemness properties, as demonstrated by elevated Nanog,
Oct3/4 and Sox2 expression.
BMI-1 is a member of the polycomb repressive complex 1 (PRC1) that functions as an epigenetic
suppressor of gene expression via heterodimerization with Ring1B/Rnf2. Ring1B/Rnf2 heterodimer
stimulates BMI-1 ubiquitin ligase activity toward lysine 119 of histone 2A (H2A-K119) [54]. BMI-1 is
recruited to CpG islands throughout the genome by transcription factors and non-coding RNAs [55] to
mediate gene silencing. Although it is well known that BMI-1 has an important role in the modulation
of self-renewal and cell differentiation potential of hematopoietic stem cells (HSCs) and neuronal stem
cells (NSCs) [34], BMI-1 is also a key regulator of the self-renewal, differentiation and tumor initiation
of CSCs. BMI-1 is expressed in a number of malignancies, such as prostate, lung, ovarian, pancreatic,
lymphoma, glioma, acute myeloid leukemia and breast cancer, among others [34] (Figure 1 [27,28]).
High levels of BMI-1 in tumor cells drive stem-like properties associated with the induction of EMT
that promotes invasion, metastasis, and an enhanced resistance to chemotherapy [56–58]. For instance,
in breast cancer, the knockdown of BMI-1 expression impaired the tumor initiation ability of CSCs,
while the rescue of BMI-1 expression restored tumor formation [59]. Moreover, high levels of BMI-1
were found in human glioblastomas, specifically in the tumor-initiating CD133 positive stem cells,
and the knockdown of BMI-1 completely prevented brain tumor formation in mice [60]. Enhanced
BMI-1 levels upon Wnt5a-ROR1 stimulation via AKT activation may indicate the existence of a
crosstalk between non-canonical Wnt pathways and BMI-1, that could regulate tumorigenesis and
drug resistance (Figure 2A). Prior reports have demonstrated a complex regulation of BMI-1 activation
via phosphorylation, since AKT-mediated phosphorylation of BMI-1 could modulate its function in
a Ink4a/Arf-independent [53] or dependent manner [61], to make BMI-1 an oncogene or a tumor
suppressor gene, respectively, with opposing effects on cancer outcome. Given the above evidence, it
appears that Wnt5a-ROR1 signaling could induce stemness and tumorigenesis via BMI-1 expression
modulation, although further studies are needed to carefully delineate the phosphorylation-dependent
regulation of the BMI-1 function downstream of the Wnt5a-ROR1 pathway.
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in turn can phosphorylate BMI-1 to promote genomic instability, cancer cell proliferation and drug-
resistance. (B) Wnt5a binding to ROR1/FZD complex will activate RhoA via Gα12/13 engagement, 
resulting in the inhibition of Lats1/2 activity and consequently, YAP/TAZ dephosphorylation and 
nuclear translocation. Binding of YAP/TAZ to TEADs can induce the transcription of genes involved 
in stemness and tumorigenesis. Increased YAP/TAZ transcription could, in turn, upregulate ROR1 
expression. RingB1, E3 ubiquitin-protein ligase RING1; FZD, Frizzled; Gα12/13, Guanine nucleotide-
binding protein subunit alpha-12/13; AKT, protein kinase B. 
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Figure 2. Crosstalk bet een Wnt5a-ROR1 signaling and BMI-1 (A) or Y P/TAZ (B) pathways.
(A) Wnt5a binding to ROR1 induces intracellular signaling, leading to an increased AKT activation
that in turn can phosphorylate BMI-1 to promote genomic instability, cancer cell proliferation and
drug-resistance. (B) Wnt5a binding to ROR1/FZD complex will activate RhoA via Gα12/13 engagement,
resulting in the inhibition of Lats1/2 activity and consequently, YAP/TAZ dephosphorylation and nuclear
translocation. Binding of YAP/TAZ to TEADs can induce the transcription of genes involved in stemness
and tumorigenesis. Increased YAP/TAZ transcription could, in turn, upregulate ROR1 expression.
RingB1, E3 ubiquitin-protein ligase RING1; FZD, Frizzled; Gα12/13, Guanine nucleotide-binding protein
subunit alpha-12/13; AKT, protein kinase B.
4. Crosstalk between Wnt5a-ROR1 and YAP/TAZ Pathways in Tu origenesis
Several studies have linked the expression of ROR1 to the activation of YAP/TAZ transcription,
leading to enhanced tumorigenesis and chemoresistance [20,21]. YAP and TAZ are transcriptional
effectors of the Hippo pathway, a key regulator of development and tissue homeostasis [62]. The core
Mammalian Ste20-like kinase 1/2-Large tumor suppressor 1/2 (Mst1/2-Lats1/2) kinase cascade from the
Hippo pathway controls the turnover of YAP/TAZ proteins via phosphorylation and ubiquitin-mediated
degradation in the cytoplasm. Upon inhibition of the Hippo pathway, activated YAP/TAZ are
translocated into the nucleus to bind TEAD family transcription factors and subsequently initiate the
expression of target genes involved in cell proliferation, stem cell self-renewal, and tumorigenesis [63].
The dysregulation of Hippo signaling is observed in many cancers and can cause YAP/TAZ oncogenic
addiction, resulting in stemness properties, proliferation, metastasis and drug-resistance [63]. For
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instance, TAZ activity is increased in poorly differentiated breast cancer tumors and correlates with
CSCs, poor prognosis and metastasis [64], making TAZ an effector for self-renewal and tumor initiation
properties of breast CSCs. Furthermore, in lung cancer, TAZ promotes tumorigenesis and stemness via
the upregulation of the CSC marker ALDH1A [65]. Elevated YAP expression has also been observed in
lung, liver, ovary, cervix, colon, and other cancers [32,33] (Figure 1 [27,28]).
Wnt5a stimulation induces the ROR1-dependent activation and nuclear accumulation of the TAZ
protein, thereby enhancing the stemness of breast cancer cells, resulting in improved cell survival,
migration and drug resistance [20]. There could be various molecular mechanisms responsible for the
Wnt5a-ROR1-mediated YAP/TAZ transcription activation. Prior studies have indicated that Wnt5a/b
ligands are able to activate YAP/TAZ via ROR1-FZD2/5 co-receptors through non-canonical Wnt
signaling [66]. Also, YAP expression significantly increased the transcription of Wnt5a only, among
other Wnt ligands, strongly indicating that YAP/TAZ are modulators of the non-canonical Wnt pathway
via the induction of Wnt5a transcription. The molecular effectors directly connecting Wnt signaling
to YAP/TAZ have been delineated to involve GPCR (G protein-coupled receptors) Gα12/13 and their
downstream Rho GTPases that are directly acting on Lats1/2 activation and thereby, YAP/TAZ turnover
(Figure 2). Prior studies have also shown that RhoA inhibits Lats1/2 to activate YAP/TAZ, while analysis
of gene expression data from cancer cell lines revealed a direct correlation between YAP/TAZ and
Wnt5a/b levels, indicating that non-canonical Wnt signaling via Wnt5a/b is able to induce YAP/TAZ
activation in cancer cells [67].
Further evidence linking the ROR1 and YAP/TAZ pathways to the modulation of CSC self-renewal
and drug resistance was provided recently by a study of T-MD1 resistance development in breast
cancer [21]. T-DM1 resistance resulted in increased cell surface levels of ROR1 along with CSC-like
properties, such as higher percentages of ALDH1+ and CD44+ in ROR1+/T-DM1-resistant breast cancer
cells. Interestingly, YAP1 was found to regulate ROR1 expression, and the disruption of YAP1-TEAD
impaired T-DM1-induced ROR1 overexpression and CSC self-renewal.
Another possible link between Hippo-YAP/TAZ and ROR1 signaling is the transcription factor
Twist1, which is known to promote EMT in cancer cells. Twist1 expression is regulated by YAP in
association with Smad2/3 [68]. Moreover, Twist1 has been shown to bind directly to the ROR1 promoter
and induce ROR1 expression in basal-like breast cancer [69], as well as to regulate the transcription of
ROR1 ligand Wnt5a [70].
Interestingly, aberrant YAP/TAZ expression has been linked to drug resistance in several cancers,
underlining a common feature with ROR1 and raising the possibility that ROR1 and YAP/TAZ signaling
reinforce each other to make cancer cells treatment resistant. YAP/TAZ overexpression could induce
resistance to taxanes and doxorubicin in breast cancer [71,72]. In taxane-resistant ovarian cancer, YAP
is activated as a result of miRNA targeting the mRNA transcription of Lats, an upstream deactivator of
YAP/TAZ [72]. Other studies have reported that increased nuclear YAP levels could promote cisplatin
resistance in ovarian cancer, squamous cell carcinoma, and urothelial cell carcinoma [71,73]. Moreover,
the transcriptional targets of YAP/TAZ, such as CTGF and CYR61, can contribute to chemoresistance
by activating the MAPK and NF-κB signaling pathways [72]. Additionally, YAP/TAZ/TEAD complexes
induce the expression of ABC multidrug transporters that promote drug eﬄux; ABCB1 and ABCC1
have been found upregulated in ovarian and liver CSCs, and ABCG2 in gastric CSCs [72].
Taken together, these studies demonstrate the existence of a Wnt5a/ROR1–YAP/TAZ feedback loop
that modulates the CSC phenotype, tumor progression, metastasis and, ultimately, drug resistance.
The ROR1-dependent regulation of BMI-1 levels constitutes another signaling niche responsible for
stemness, metastasis and drug resistance. Therefore, a better understanding of the crosstalk between
the non-canonical Wnt pathway (Wnt5a/ROR1) and YAP/TAZ transcription or BMI-1 functional
modulation would enable us to find more optimal therapeutic targets to overcome disease progression
and treatment resistance.
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5. Progress in ROR1-Targeted Therapies
The emergence of ROR1 as a marker for CSCs implies that ROR1-positive tumors have a high
resistance to treatment. Indeed, ROR1-positive carcinomas were associated with aggressive disease
progression and lower rates of progression-free survival or overall survival rates of patients, as well as
treatment resistance, suggesting a high potential for ROR1-targeted therapies during advanced disease
stages. The extracellular domain of ROR1 is typically targeted using antibody-based agents, and
several of such antibodies have shown promising results in preclinical or clinical settings. Anti-ROR1
monoclonal antibody cirmtuzumab (UC-961) has completed a phase 1 clinical trial for CLL with
encouraging results, as demonstrated by the inhibition of Wnt5a/ROR1 signaling in ROR1-positive
leukemic cells, and a phase 1b/2 combination clinical trial has been initiated for patients with CLL
and MCL [38]. Multiple preclinical studies have indicated that combination therapies co-targeting
ROR1 and other oncogenic pathways are more effective in killing drug-resistant cancer cells than a
single agent alone. For instance, co-treatment of breast cancer PDXs with cirmtuzumab and paclitaxel
achieved a greater cytotoxic effect than a single treatment [20]. In similar studies for hematological
cancers, the combination of cirmtuzumab and ibrutinib was more efficient in eradicating leukemic
cells in vivo [74], whereas the ex vivo co-targeting of ROR1 and Bcl-2 in CLL, MCL or B-ALL patient
samples was significantly more effective than targeting a single pathway, strongly supporting the
implementation of these combinatorial regimens in clinical trials [13,39,40]. Apart from cirmtuzumab,
other ROR1 monoclonal antibodies have been developed and tested at preclinical levels [75]. A potent
immunotherapeutic approach was used to develop bispecific antibodies (biAbs) that combine a T
cell-engaging arm with a tumor cell-binding arm, for which ROR1 seemed a perfect candidate due to
its relatively restricted expression on tumor cells. A ROR1-targeting scFv with a membrane-proximal
epitope, R11, which binds to the Kringle domain of ROR1, showed promising in vivo and ex vivo
cytotoxicity against ROR1-positive cancer cells [76].
Moreover, ARI-1 ((R)-5,7-bis(methoxymethoxy)-2-(4-methoxyphenyl)chroman-4-one) inhibitor,
targeting the extracellular Frizzled-like domain (CRD or cysteine-rich domain) of ROR1, produced
promising results in chemoresistant NSCLC models [77]. Targeting the intracellular domains of ROR1
has posed more challenges, due to the lack of structural data for the cytoplasmic portion of this
receptor. We therefore believe that more opportunities will present themselves once there are advances
in understating the structural and functional aspects of ROR1 signaling mechanisms. This will have
great implications for ROR1-targeted therapies, as well for the basic research of Wnt-signaling in
development and disease.
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